Pathology: metastatic/advanced OC (mOC) - 2nd line (L2); metastatic/advanced OC (mOC) - maintenance (M);
| metastatic/advanced OC (mOC) - 2nd line (L2) | metastatic/advanced OC (mOC) - maintenance (M) | |||
| JAVELIN ovarian 200 (A vs doxorubicin), 2021 | JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 | JAVELIN Ovarian 100, 0 | ||
| avelumab plus SoC | 1 | T1 | ||
| avelumab alone | 1 | T1 | ||
| avelumab plus pegylated liposomal doxorubicin | 1 | T1 | ||
| Standard of Care (SoC) | 0 | T0 | ||
| pegylated liposomal doxorubicin | 0 | T0 | T0 | |